{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Halabi S"],"funding":["Cancer Research UK","NCI NIH HHS"],"pagination":["64-72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8580377"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(3)"],"pubmed_abstract":["Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for therapy. We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. The primary endpoint was overall survival (OS) and secondary efficacy endpoints for this exploratory biomarker analysis were radiographic progression-free survival (rPFS) defined by intention-to-treat using the RECIST 1.1 criter"],"journal":["Kidney cancer journal : official journal of the Kidney Cancer Association"],"pubmed_title":["Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial."],"pmcid":["PMC8580377"],"funding_grant_id":["P30 CA021765","25355","P30 CA014236"],"pubmed_authors":["George DJ","Jones RJ","Ryan CW","Stadler WM","Garcia JA","Foo WC","Halabi S","Kollmannsberger CK","Zhang S","Vaishampayan UN","Eisen T","Pickering LM","Carmack A","Logan TF","Protheroe A","Yang Q","Picus J","Hainsworth JD","Armstrong AJ","Hawkins RE","Puzanov I"],"additional_accession":[]},"is_claimable":false,"name":"Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.","description":"Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for therapy. We enrolled 108 patients in ASPEN, an international randomized open-label phase 2 trial of patients with metastatic papillary, chromophobe, or unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), stratified by MSKCC risk and histology. The primary endpoint was overall survival (OS) and secondary efficacy endpoints for this exploratory biomarker analysis were radiographic progression-free survival (rPFS) defined by intention-to-treat using the RECIST 1.1 criter","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-07T19:38:25.242Z","creation":"2022-02-11T12:57:42.814Z"},"accession":"S-EPMC8580377","cross_references":{"pubmed":["34765076"],"doi":["10.52733/kcj19n3-a1"]}}